Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) CFO William Duke sold 22,355 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60. Following the sale, the chief financial officer owned 187,362 shares in the company, valued at $134,900.64. This trade represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Invivyd Stock Performance
Shares of IVVD opened at $0.96 on Thursday. The stock has a market capitalization of $282.82 million, a PE ratio of -2.91 and a beta of 0.71. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07. The company’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $1.23.
Invivyd (NASDAQ:IVVD – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. On average, sell-side analysts predict that Invivyd, Inc. will post -0.52 earnings per share for the current year.
Institutional Investors Weigh In On Invivyd
Key Invivyd News
Here are the key news stories impacting Invivyd this week:
- Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
- Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
- Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
- Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.
Analysts Set New Price Targets
IVVD has been the subject of several research reports. HC Wainwright restated a “buy” rating on shares of Invivyd in a research note on Tuesday. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Finally, Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Invivyd has a consensus rating of “Hold” and a consensus target price of $8.00.
Get Our Latest Report on Invivyd
Invivyd Company Profile
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Read More
- Five stocks we like better than Invivyd
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
